Skip to search formSkip to main contentSkip to account menu

PCI 0123

Known as: PCI-0123 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
New photosensitizers proposed for photodynamic therapy (PDT) treatment of tumors need to be evaluated in animal models to… 
Highly Cited
1998
Highly Cited
1998
Photodynamic therapy (PDT) of pigmented melanoma has generally been unsuccessful because of insufficient light penetration in… 
1998
1998
Photodynamic therapy (PDT) of locally recurrent breast cancer has been limited to treatment of small lesions because of non… 
Highly Cited
1997
Highly Cited
1997
Lutetium texaphyrin (PCI-0123) is a pure, water-soluble photodynamic therapy (PDT) agent that is activated by tissue-penetrating… 
1997
1997
Lutetium texaphyrin (PCI-0123) is presently in clinical trials for the treatment of neoplasms. An argon-pumped dye laser has… 
1997
1997
Lutetium texaphyrin (PCI-0123) is currently in clinical trials as a PDT agent for the treatment of cancer patients. The drug is… 
1997
1997
Cardiovascular disease is the chief cause of death in the western world. Lutetium texaphyrin (PCI-0123) is a pure, synthetic… 
Highly Cited
1996
Highly Cited
1996
Lutetium texaphyrin, PCI‐0123, is a pure, water‐soluble photosensitizer with a large broad absorption band centered at 732 nm… 
Highly Cited
1996
Highly Cited
1996
Cancer and cardiovascular disease are the leading causes of death in the western world. Photodynamic therapy (PDT) has…